investigators presented noteworthy findings on an innovative gene therapy for sickle cell disease, CAR T-cell therapy in high-risk large B cell lymphoma, and research in stem cell transplantation.
In this in-between-isode of MedPage Today s Podcast series, Anamnesis, one of our reporters discusses some of these data.
Host: Hello, and thanks for joining us for the latest in-between-isode of Anamnesis.
ASH 2020 was a virtual event this year due to COVID-19, but
MedPage Today s reporter, Ian Ingram, followed all the major developments from the conference. Ingram: One notable study at this year s ASH meeting found that older, high-risk patients with myelodysplastic syndromes, or MDS, lived significantly longer when they underwent allogeneic hematopoietic stem-cell transplantation.
ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Gene-editing treatment shows promise for sickle cell disease
japantoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantoday.com Daily Mail and Mail on Sunday newspapers.
New Treatments for Lymphoma, Leukemia Unveiled at Cancer Conference
Written by Jamie Reno on December 11, 2020 Fact checked by Jennifer Chesak
Encouraging news on cancer treatments such as CAR-T therapy and monoclonal antibodies was announced at an annual conference. Luis Alvarez/Getty Images
Updates on treatments for blood cancers such as leukemia and lymphoma were presented at the annual conference of the American Society of Hematology.
Scientists reported on further advancements in CAR-T therapies that boost a person’s immune system to fight cancers.
There were also reports of promising results of drugs known as monoclonal antibodies.
Every December, the American Society of Hematology (ASH) holds its Annual Meeting and Exposition.